These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 211087)

  • 1. Vascular permeability changes in the central nervous system of rats with hyperacute experimental allergic encephalomyelitis induced with the aid of a substance from Bordetella pertussis.
    Bergman RK; Munoz JJ; Portis JL
    Infect Immun; 1978 Aug; 21(2):627-37. PubMed ID: 211087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypothermia due to an ascending impairment of shivering in hyperacute experimental allergic encephalomyelitis in the Lewis rat.
    Hansen LA; Pender MP
    J Neurol Sci; 1989 Dec; 94(1-3):231-40. PubMed ID: 2614469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperacute allergic encephalomyelitis: a single determinant.
    Westall FC
    Immunol Commun; 1977; 6(3):227-37. PubMed ID: 69608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitigation of experimental allergic encephalomyelitis by cathepsin D inhibition.
    Boehme DH; Marks N
    Adv Exp Med Biol; 1979; 121B():317-23. PubMed ID: 317560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat.
    Stohl W; Gonatas NK
    J Immunol; 1978 Sep; 121(3):844-50. PubMed ID: 308523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic relapsing experimental allergic encephalomyelitis in the Lewis rat.
    Feurer C; Prentice DE; Cammisuli S
    J Neuroimmunol; 1985 Dec; 10(2):159-66. PubMed ID: 3877741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of the clinical and histopathologic expression of experimental allergic encephalomyelitis by the vasoactive amine antagonist cyproheptadine.
    Waxman FJ; Taguiam JM; Whitacre CC
    Cell Immunol; 1984 Apr; 85(1):82-93. PubMed ID: 6201289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of experimental allergic encephalomyelitis in mice with the aid of pertussigen from Bordetella pertussis.
    Munoz JJ; Mackay IR
    Cell Immunol; 1984 Jul; 86(2):541-5. PubMed ID: 6329525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Bordetella pertussis vaccine on experimental autoimmune encephalomyelitis in rats.
    Källén B; Nilsson O
    Int Arch Allergy Appl Immunol; 1986; 80(1):95-9. PubMed ID: 3485580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogation of resistance to the reinduction of experimental allergic encephalomyelitis by pertussigen.
    Waxman FJ; Bergman RK; Munoz JJ
    Cell Immunol; 1982 Sep; 72(2):375-83. PubMed ID: 6185237
    [No Abstract]   [Full Text] [Related]  

  • 11. The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.
    Pender MP; Stanley GP; Yoong G; Nguyen KB
    Acta Neuropathol; 1990; 80(2):172-83. PubMed ID: 2389682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation between the increase in the diffusional permeability of the blood-central nervous system barrier and other changes during the development of experimental allergic encephalomyelitis in the Lewis rat.
    Daniel PM; Lam DK; Pratt OE
    J Neurol Sci; 1983; 60(3):367-76. PubMed ID: 6415240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in the effectiveness of the blood-brain and blood-spinal cord barriers in experimental allergic encephalomyelitis.
    Daniel PM; Lam DK; Pratt OE
    J Neurol Sci; 1981; 52(2-3):211-9. PubMed ID: 6796652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic enzymes in ordinary, hyperacute, monocytic and passive transfer forms of experimental allergic encephalomyelitis.
    Marks N; Grynbaum A; Levine S
    Brain Res; 1977 Mar; 123(1):147-57. PubMed ID: 843913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen, host and adjuvant requirements for induction of hyperacute experimental autoimmune encephalomyelitis.
    Lennon VA; Westall FC; Thompson M; Ward E
    Eur J Immunol; 1976 Nov; 6(11):805-10. PubMed ID: 63374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).
    Boehme DH; Umezawa H; Hashim G; Marks N
    Neurochem Res; 1978 Apr; 3(2):185-94. PubMed ID: 307703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat.
    Juhler M; Barry DI; Offner H; Konat G; Klinken L; Paulson OB
    Brain Res; 1984 Jun; 302(2):347-55. PubMed ID: 6610460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALLERGIC ENCEPHALOMYELITIS: A HYPERACUTE FORM.
    LEVINE S; WENK EJ
    Science; 1964 Dec; 146(3652):1681-2. PubMed ID: 14224517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hyperacute form of allergic encephalomyelitis produced in rats without the aid of pertussis vaccine.
    Levine S; Saltzman A
    J Neuropathol Exp Neurol; 1989 May; 48(3):255-62. PubMed ID: 2784830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of various immunomodulators on the induction of experimental autoimmune encephalomyelitis in Lewis rats.
    Sedlacek HH; Wanger R; Bengelsdorff HJ
    Immunobiology; 1980 Jul; 157(2):99-108. PubMed ID: 6250977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.